| Amitiza (lubiprostone) / Takeda, Mallinckrodt |
NCT04985669: Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome |
|
|
| Recruiting | 4 | 140 | RoW | Prucalopride 2mg, calopride | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Patient Satisfaction | 02/22 | 03/22 | | |
ChiCTR2400088155: Evaluating lubiprostone for effective in colonoscopic bowel preparation |
|
|
| Not yet recruiting | 4 | 244 | | Use of rupiprostenone before bowel preparation; Use of rupiprostenone before bowel preparation; control group 1 ; control group 12 | The Affiliated People’s Hospital of Ningbo University; The Affiliated People’s Hospital of Ningbo University, self-finance | Bowel Preparation | | | | |
ChiCTR2400090921: A Randomized Controlled Study of the Efficacy and Safety of a Bowel Preparation Regimen of 1L Polyethylene Glycol Combined with Lubiprostone Versus 2L Polyethylene Glycol |
|
|
| Not yet recruiting | 4 | 284 | | 1L Polyethylene Glycol (PEG) + Lubiprostone; 2L Polyethylene Glycol (PEG) | The First Affiliated Hospital Of Guangzhou Medical University; The First Affiliated Hospital Of Guangzhou Medical University, Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd | Bowel preparation protocol before colonoscopy | | | | |
ChiCTR2400090127: Efficacy and Safety of Lubiprostone Compared to Lactulose in Elderly Patients with Chronic Constipation: A Randomized, Controlled, Open-Label, Multicenter Clinical Study |
|
|
| Not yet recruiting | 4 | 190 | | Subjects will take Lubiprostone capsules orally for 4 consecutive weeks, 24 μg per capsule, 1 capsule per dose, twice daily; Subjects will take lactulose solution orally for 4 consecutive weeks, starting with an initial dose of 30 mL per day. The maintenance dose will be 10-25 mL per day, administered orally, for a total duration of 4 weeks. | Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Corporate Sponsorship | Chronic constipation | | | | |
ChiCTR1800015360: The efficacy and safety of Lubiprostone capsule in the treatment of functional constipation: a randomized, double-blind, multi-center, placebo-parallel-controlled Confirmatory clinical trial |
|
|
| Not yet recruiting | 3 | 260 | | lubiprostone capsules ;Placebo capsules | The First Affiliated Hospital of Sun Yat-sen University; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised | functional constipation | | | | |
NCT05768334: Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease |
|
|
| Completed | 3 | 116 | RoW | Lubiprostone 24Mcg Oral twice daily | Helwan University | NAFLD | 02/23 | 02/23 | | |
NCT06543979: Anorectal Manometery in Pediatric Chronic Refractory Constipation |
|
|
| Recruiting | 1/2 | 60 | RoW | lubiprostone , single arm, lubicont, biofeed back sessions, botox injection | Ain Shams University | Chronic Constipation | 09/25 | 10/25 | | |
| Recruiting | N/A | 3000 | RoW | No Intervention | Jeil Pharmaceutical Co., Ltd. | Constipation | 05/24 | 11/24 | | |
NCT03720613: Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain |
|
|
| Recruiting | N/A | 34532 | US | Naldemedine, Symproic®, Lubiprostone, Amitiza®, Naloxegol, Movantik® | BioDelivery Sciences International, HealthCore, Inc. | Opioid-induced Constipation | 11/30 | 11/30 | | |
| Mytesi (crofelemer) / Jaguar Health, Knight Therap |
NCT03898856: Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients |
|
|
| Recruiting | 4 | 100 | US | Crofelemer, Diagnostic tests for cause of chronic diarrhea | The University of Texas Health Science Center, Houston, Napo Pharmaceuticals, Inc. | Chronic Diarrhea of Unknown Origin | 10/24 | 12/24 | | |
| Completed | 3 | 287 | US, RoW | Crofelemer 125 MG [Mytesi], Placebo | Napo Pharmaceuticals, Inc. | Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea | 08/23 | 10/23 | | |
NCT06721871: Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) |
|
|
| Not yet recruiting | 2 | 12 | Europe, US, RoW | Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution | Napo Pharmaceuticals, Inc. | Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases | 12/25 | 03/26 | | |
NCT06326645: Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome |
|
|
| Not yet recruiting | 1 | 6 | US | Crofelemer Oral Product | Lindsey Russell, MD, Napo Pharmaceuticals, Inc. | Short Bowel Syndrome | 12/25 | 12/25 | | |
NCT05804396: Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine |
|
|
| Withdrawn | N/A | 57 | NA | Relivion® | Neurolief Ltd. | Migraine | 11/24 | 11/24 | | |
| moxidectin / Generic mfg. |
| Completed | 3 | 224 | RoW | Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Zentel®, Placebo MOX, Placebo ALB | Jennifer Keiser, Public Health Laboratory Ivo de Carneri | Trichuriasis, Ascariasis, Hookworm Infections | 08/24 | 08/24 | | |
NCT03876262: Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis |
|
|
| Active, not recruiting | 3 | 323 | RoW | Moxidectin, Ivermectin | Medicines Development for Global Health | Onchocerciasis | 07/24 | 07/26 | | |
NCT04311671: Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole |
|
|
| Completed | 3 | 12997 | RoW | Moxidectin, Ivermectin, Albendazole | Medicines Development for Global Health | Onchocerciasis | 09/24 | 09/24 | | |
| Active, not recruiting | 3 | 164 | RoW | Ivermectin, Stromectol, Diethylcarbamazine, Diethylcarbamazine citrate, Hetrazan, Albendazole, Moxidectin | Washington University School of Medicine, Case Western Reserve University, Regional Hospital of Agboville, Southern Cote d'Ivoire | Lymphatic Filariasis | 09/24 | 09/24 | | |
StrongMoxy, NCT04056325: Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis |
|
|
| Completed | 2/3 | 617 | RoW | Moxidectin, Ivermectin, Placebo oral tablet | Jennifer Keiser, National Institute of Public Health, Vientiane, Laos | Strongyloides Stercoralis Infection | 04/21 | 04/21 | | |
2019-001775-37: Dose-finding study of moxidectin for the treatment of scabies |
|
|
| Not yet recruiting | 2 | 36 | Europe | Moxidectin, Tablet, Moxidectin | Medicines Development Limited (trading as Medicines Development for Global Health), Medicines Development for Global Health Limited, Medicines Development Limited, Medicines Development for Global Health Limited | Scabies (infection with Sarcoptes scabiei), Scabies, Diseases [C] - Parasitic Diseases [C03] | | | | |
EOLoa, NCT04049851: Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients |
|
|
| Active, not recruiting | 2 | 72 | RoW | Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | Onchocerciasis, Ocular, Loiasis | 08/23 | 08/23 | | |
NCT05875441: Efficacy and Safety Study of Moxidectin in Adults with Scabies |
|
|
| Active, not recruiting | 2 | 200 | US, RoW | Moxidectin Oral Product, Placebo | Medicines Development for Global Health | Scabies | 11/24 | 02/25 | | |
NCT06070116: Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis |
|
|
| Enrolling by invitation | 2 | 300 | RoW | Ivermectin w/ Albendazole, IA, Ivermectin + Diethylcarbamazine + Albendazole, IDA, Moxidectin + Albendazole, MoxA, Moxidectin + Diethylcarbamazine + Albendazole, MoxDA | Washington University School of Medicine, National Public Health Institute of Liberia | Onchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular, Onchocerca Infection, Tropical Disease | 09/26 | 09/26 | | |
| ivermectin extended release (LYN‐063) / Lyndra |
ACTRN12621001218886: An Open-label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LYN-163 in Healthy Volunteers |
|
|
| Completed | 1 | 25 | | | Lyndra®Therapeutics, Inc. (Lyndra), Lyndra®Therapeutics, Inc. (Lyndra) | Malaria | | | | |
| ivermectin oral / Generic mfg. |
ACTRN12611000906954: Development of a screening and treatment program using oral ivermectin to manage pediculosis capitis (head lice) in primary schools |
|
|
| Not yet recruiting | 4 | 2000 | | | Australian National University, Australian National University, The Australian National University | Head lice infestation | | | | |
ACTRN12619001712190p: A trial of community wide treatment to reduce scabies in a village setting in northern India |
|
|
| Not yet recruiting | 4 | 2200 | | | The Nossal Institute for Global Health (University of Melbourne), The Nossal Institute for Global Health (University of Melbourne) | Scabies
| | | | |
ACTRN12619001712190: A trial of community wide treatment to reduce scabies in a village setting in northern India |
|
|
| Recruiting | 4 | 2200 | | | The Nossal Institute for Global Health (University of Melbourne), The Nossal Institute for Global Health (University of Melbourne), International Dermatology Outreach Program | Scabies
| | | | |
| Ongoing | 4 | 50 | Europe | ivermectin, ivermectin, ivermectin | Queen Victoria Hospital, Kidney Transplant & Diabetes Research Australia | Demodex Follicularum associated anterior blepharitis | | | | |
IDRA-COVID19, NCT04435587: Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection |
|
|
| Recruiting | 4 | 80 | RoW | Ivermectin Pill, Vermectin, Combined ART/hydroxychloroquine, combined darunavir/ritonavir/hydroxychloroquine | Mahidol University | Asymptomatic Infections, SARS-CoV2 Infection | 06/21 | 11/21 | | |
COVIVER-OUT PLUS, NCT04729140: An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization |
|
|
| Recruiting | 4 | 150 | US | Ivermectin Tablets, Doxycycline Tablets, Placebo | Max Health, Subsero Health | Covid19 | 12/21 | 03/22 | | |
NCT04944082: Remdesivir- Ivermectin Combination Therapy in Severe Covid-19 |
|
|
| Not yet recruiting | 4 | 60 | NA | Ivermectin | Assiut University | Covid19 | 12/21 | 12/21 | | |
| Completed | 4 | 60 | RoW | Ivermectin Tablets, Permethrin Cream | Universitas Padjadjaran | Scabies | 02/23 | 03/23 | | |
NCT06332872: Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand |
|
|
| Active, not recruiting | 4 | 117 | RoW | Oral Ivermectin, 4% dimenticone liquid gel | Phramongkutklao College of Medicine and Hospital | Pediculus Capitis Infestation, Permethrin Adverse Reaction, Dimethicone Adverse Reaction, Permethrin Allergy, Dimethicone Allergy, Ivermectin, School-age Children | 03/24 | 05/24 | | |
ACTRN12620000982910: A randomized double-blind placebo-controlled trial of oral ivermectin for outpatient treatment of those at high risk for hospitalization due to COVID-19 |
|
|
| Not yet recruiting | 3 | 400 | | | Neuroscience Trials Australia, The Leona M and Harry B Helmsley Charitable Trust (The United States of America). | SARS-CoV-2 (COVID-19), | | | | |
| Not yet recruiting | 3 | 1000 | | | Monash University, The Leona M and Harry B Helmsley Charitable Trust | COVID-19; SARS-CoV-2 | | | | |
NCT06259383: Oral Ivermectin for Chikungunya Viral Infection |
|
|
| Completed | 3 | 120 | RoW | Ivermectin | Prince of Songkla University | Clinical Syndrome | 12/21 | 01/24 | | |
2020-001994-66: Study of the efficacy of ivermectin in the treatment and prevention of COVID-19 Estudio de la eficacia de ivermectina en el tratamiento y la prevención de COVID-19 |
|
|
| Ongoing | 3 | 266 | Europe | STROMECTOL 3 mg, 34009 352 388 5 6, Tablet, STROMECTOL 3 mg | Fundació Assistencial Mútua Terrassa, Fundació Docència i Recerca Mútua Terrassa | SARS COVID-19 SARS COVID-19, Coronavirus infection Infección por coronavirus, Diseases [C] - Virus Diseases [C02] | | | | |
2020-001971-33: Pragmatic study "CORIVER": Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID19) PRUEBA DE CONCEPTO “CORIVERâ€: IVERMECTINA COMO TRATAMIENTO ANTIVÃRICO EN PACIENTES INFECTADOS POR EL SARS-COV2 (COVID19) |
|
|
| Ongoing | 3 | 45 | Europe | Ivermectin, dolquine, azithromycin, Ivermectin, Hydroxychloroquine, azithromycin, Tablet, Ivermectin, Dolquine, Azitromicina Vir 500 mg | Carmen Hidalgo, Hospital Universitario Virgen de las Nieves | SARS-COV2 SARS-COV2, New Coronavirus infection Infección por el coronavirus, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Active, not recruiting | 3 | 4124 | RoW | Ivermectin, Iver P, Placebo oral tablet | Brian Foy, Yale University, Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest, Radboud University Medical Center, PATH, National Institute of Allergy and Infectious Diseases (NIAID) | Malaria | 11/20 | 08/24 | | |
2020-005423-37: Evaluation of an ivermectin single dose administration for the early phase of COVID-19 treatment. Évaluation de l'administration d'une dose unique d'ivermectine pour le traitement de la phase précoce de la COVID-19. |
|
|
| Not yet recruiting | 3 | 200 | Europe | Ivermectine Pierre Fabre 3 mg, Buccal tablet, IVERMECTINE PIERRE FABRE 3 mg, comprimé | Raincy Montfermeil intercommunal hospital group, Internal COVID 19 Grant | patients with COVID 19 symptoms for less than 72 hours Patients avec symptômes covid 19 de moins de 72 heures, patients with COVID 19 symptoms for less than 72 hours Patients avec symptômes covid 19 de moins de 72 heures, Diseases [C] - Virus Diseases [C02] | | | | |
2020-005015-40: Ivermectin to prevent SARS-CoV-2 (COVID-19) hospitalisation in subjects over 50 Použitie ivermektÃnu na prevenciu hospitalizácie úÄastnÃkov so SARS-CoV-2 (COVID-19) vo veku nad 50 rokov |
|
|
| Ongoing | 3 | 832 | Europe | Ivermectin 9 mg tablets, Ivermectin 18 mg tablets, Tablet | Chemo Research S.L., Chemo Research S.L. | Coronavirus disease (COVID-19) Ochorenie koronavÃrusom (COVID-19), Coronavirus disease (COVID-19) Ochorenie koronavÃrusom (COVID-19), Diseases [C] - Virus Diseases [C02] | | | | |
NCT04834115: Efficacy of Ivermectin in Outpatients With Non-severe COVID-19 |
|
|
| Recruiting | 3 | 400 | RoW | Ivermectin Tablets, Placebo | Universidad Nacional de Asunción, Consejo Nacional de Ciencias y Tecnologia, Paraguay, Ministerio de Salud Pública y Bienestar Social, Paraguay, Centro de información y recursos para el desarrollo, Paraguay, Centro para el Desarrollo de la Investigación CientÃfica, CEDIC, Paraguay, Instituto Desarrollo, Paraguay | Covid19, Coronavirus Infection | 04/21 | 05/21 | | |
| Recruiting | 3 | 80 | RoW | Ivermectin Powder, Direct antiviarl agents | Mansoura University | COVID-19 | 04/21 | 12/21 | | |
NCT04937569: Ivermectin Versus Standard Treatment in Mild COVID-19 |
|
|
| Not yet recruiting | 3 | 1644 | RoW | Ivermectin Tablets | Assiut University | Covid19 | 09/21 | 11/21 | | |
2021-002445-15: Studie zur Wirksamkeit und Sicherheit von Ivermectin Tabletten (Driponin®) für die Prophylaxe der COVID-19 Erkrankung Studie zur Wirksamkeit und Sicherheit von Ivermectin Tabletten (Driponin®) für die Prophylaxe der COVID-19 Erkrankung |
|
|
| Ongoing | 3 | 412 | Europe | Tablet, DRIPONIN 3 mg Tabletten | InfectoPharm Arzneimittel und Consilium GmbH, InfectoPharm Arzneimittel und Consilium GmbH | COVID-19 Post-Expositionsprophylaxe COVID-19 Post-Expositionsprophylaxe, Verhinderung der COVID-19 Erkrankung nach engem Kontakt mit einer an COVID-19 erkrankten Person Verhinderung der COVID-19 Erkrankung nach engem Kontakt mit einer an COVID-19 erkrankten Person, Diseases [C] - Virus Diseases [C02] | | | | |
| Terminated | 3 | 51 | US | Ivermectin, Stromectol | Albert Einstein College of Medicine | Strongyloides Stercoralis Infection, Strongyloidiasis | 02/15 | 02/15 | | |
| Completed | 3 | 133 | Europe | Ivermectin 200 µg/kg, Ivermectin 400 µg/kg | Assistance Publique - Hôpitaux de Paris | Gale, Severe Forms of Scabies, Oral Parasitic Drug, Ivermectin | 01/22 | 01/22 | | |
NCT04510194: COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) |
|
|
| Completed | 3 | 1323 | US | Metformin, glucophage, Placebo, Fluvoxamine, Luvox, Ivermectin, Stromectol | University of Minnesota, UnitedHealth Group, Northwestern University, Hennepin County Medical Center, Minneapolis, University of Colorado, Denver, Olive View-UCLA Education & Research Institute | Covid19, SARS-CoV Infection | 02/22 | 02/22 | | |
NCT05060666 / 2021-002445-15: Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen] |
|
|
| Not yet recruiting | 3 | 412 | NA | Ivermectin, Driponin, ATC-code P02CF01, Substance code SUB12089MIG, Placebo | Infectopharm Arzneimittel GmbH, GKM Gesellschaft für Therapieforschung mbH | Covid19 | 03/22 | 03/22 | | |
NCT05736861: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) |
|
|
| Completed | 3 | 1800 | US | Ivermectin, Ivermectin Tablets, Placebo | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 03/22 | 05/22 | | |
NCT05894538: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) |
|
|
| Completed | 3 | 1459 | US | Ivermectin, Ivermectin Tablets, Placebo | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 08/22 | 10/22 | | |
| Completed | 3 | 1030 | Japan, RoW | K-237 0.3-0.4mg/kg (once daily), Ivermectin 0.3-0.4mg/kg (once daily), Placebo 0.3-0.4mg/kg (once daily) | Kowa Company, Ltd. | Covid19 | 08/22 | 08/22 | | |
| Recruiting | 3 | 24000 | RoW | Ivermectin, Placebo, Dihydroartemisinin-piperaquine, Eurartesim | London School of Hygiene and Tropical Medicine, Medical Research Council Unit, The Gambia, Ministerio de Saude Publica, Guinee-Bissau, Bandim Health Project, Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau | Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis, Lymphatic Filariasis, Scabies, Hook Worm, Soil Transmitted Helminths | 03/23 | 08/23 | | |
| Active, not recruiting | 3 | 53000 | RoW | Albendazole Pill, Alben, Bendex, Ivermectin Pill, Stromectol, Ivermectin Injectable Product, Veterinary Ivermectin 1% | Barcelona Institute for Global Health, UNITAID | Malaria | 04/24 | 10/24 | | |
FACEITeffic, NCT06037876: Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura |
|
|
| Completed | 3 | 161 | RoW | IVM (200 µg/kg) + ALB (400 mg), Zentel® and Stromectol®, Ivermectin Tablet 3mg, ALB (400mg), Zentel® | Jennifer Keiser, Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Uganda | Trichuriasis | 11/23 | 11/23 | | |
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications |
|
|
| Completed | 3 | 10956 | US | Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 04/24 | 04/24 | | |
| Completed | 3 | 1000 | | | Monash University, The Leona M and Harry B Helmsley Charitable Trust | COVID-19, SARS-CoV-2 | | | | |
| Not yet recruiting | 2/3 | 966 | NA | Ivermectin, Placebo | Ayudas Diagnosticas Sura S.A.S | COVID-19 Pneumonia | 09/21 | 12/21 | | |
NCT05283954: Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea |
|
|
| Withdrawn | 2/3 | 954 | NA | Combination regimen: Fluoxetine, Prednisolone, Ivermectin, Combination regimen: Albendazole, Vitamin C | Oriol Mitja, National Department of Health, Papua New Guinea, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | SARS-CoV2 Infection, COVID-19 | 06/22 | 07/22 | | |
| Not yet recruiting | 2 | 60 | NA | Ivermectin nasal, ivermectin, Ivermectin oral, standard care | Tanta University | Covid19 | 10/20 | 12/20 | | |
2021-000166-15: A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients |
|
|
| Ongoing | 2 | 70 | Europe | Stromectol, Tablet, Stromectol | Meditop Gyógyszeripari Kft, Meditop Gyógyszeripari Kft | COVID 19 infection COVID 19 fertÅ‘zés, Coronavirus infection KoronavÃrus fertÅ‘zés, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04703205: Study in COvid-19 Patients With iveRmectin (CORVETTE-01) |
|
|
| Active, not recruiting | 2 | 214 | Japan | Ivermectin 3 MG, Placebo | Kitasato University | Covid19 | 10/21 | 05/22 | | |
| Recruiting | 2 | 200 | RoW | Ivermectin Tablets, Placebo | Mahidol University, Prince of Songkla University | COVID-19 | 06/22 | 06/22 | | |
2021-001938-19: A MULTICENTRE CLINICAL STUDY TO EVALUATE THE EFFICACY ANDSAFETY OF IVERMECTIN IN PREVENTION OF COVID-19 |
|
|
| Not yet recruiting | 2 | 400 | Europe | Ivermectine Substipharm 3mg, tablet, Tablet, Ivermectine Substipharm 3 mg, tablet | MedinCell S.A., MedinCell S.A. | Prophylaxis of COVID-19 infection, Prevention of COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04913610: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection |
|
|
| Terminated | 2 | 153 | RoW | ABBV-4083, Tylamac, Placebo for ABBV-4083, Albendazole, Zentel, Placebo for Albendazole | AbbVie, Drugs for Neglected Diseases | Onchocerciasis | 08/23 | 08/23 | | |
2022-004143-27: Clinical trial with ivermectin to treat strongyloidiasis with the aim of demonstrating that both the independent and weight-dependent dose of the patient have the same response Ensayo clínico con ivermectina para tratar la estrongiloidiasis con el objetivo de demostrar que tanto la dosis independiente como dependiente de peso del paciente tiene la misma respuesta |
|
|
| Not yet recruiting | 2 | 276 | Europe | Ivermectin, Tablet | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Instituto de Salud Carlos III | Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality. La estrongiloidiasis está causada por un parásito que está globalmente distribuido por áreas tropicales y sub-tropicales. La mayoría de pacientes con estrongiloidiasis se encuentran asintomáticos o presentan síntomas leves con alteraciones gastrointestinales, síntomas respiratorios y lesiones cutáneas. En situaciones de defensas bajas (pacientes en tratamiento con corticoides, en trasplantados de órgano u otras situaciones) pueden presentar complicaciones graves con elevada mortalidad., Strongyloidiasis is caused by a parasite that is distributed throughout tropical and subtropical areas. Most patients are asymptomatic or with mild symptoms. La estrongiloidiasis está causada por un parásito que está distribuido por áreas tropicales y sub-tropicales. La mayoría de pacientes se encuentran asintomáticos o con síntomas leves., Diseases [C] - Parasitic Diseases [C03] | | | | |
ITCHY, NCT05500326: Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age ( Study) |
|
|
| Not yet recruiting | 2 | 120 | RoW | Ivermectin Tablets | Murdoch Childrens Research Institute, Burnet Institute, Lao Tropical and Public Health Institute | Scabies; Itch, Scabies | 06/26 | 06/26 | | |
| Recruiting | 2 | 399 | RoW | Oral ivermectin, NT007, Liconsa Laboratorios, Permethrin Cream, Pioletal® Plus, Placebo tablet, Placebo cream | University of Oxford, Fundação Alfredo da Matta (FUAM), Kenya Medical Research Institute, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), Medical Research Center Unit The Gambia (MRCG) | Scabies | 12/24 | 12/24 | | |
NCT06373835: Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis |
|
|
| Completed | 2 | 202 | RoW | Emodepside | Swiss Tropical & Public Health Institute, National Institute of Public Health, Vientiane, Laos | Strongyloides Stercoralis Infection, Strongyloidiasis | 09/24 | 09/24 | | |
| Completed | 2 | 260 | RoW | Ivermectin 1.5 mg ODT, Ivermectin 3 mg Oral Tablet, Stromectol®, Albendazole 400 mg Oral Tablet, Zentel®, Placebo IVM ODT | Jennifer Keiser, Public Health Laboratory Ivo de Carneri | Trichuriasis, Ascariasis, Hookworm Infections | 08/24 | 08/24 | | |
| Not yet recruiting | 2 | 66 | RoW | CHILD-IVITAB | University of Oxford, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta (FUAM), University of Basel, ClinSearch | Scabies | 09/25 | 12/25 | | |
| Active, not recruiting | 2 | 578 | RoW | emodepside, BAY 44-4400, matching placebo of emodepside, ivermectin, Mectizan, Stromectol, matching placebo of ivermectin | Drugs for Neglected Diseases, Bayer | Onchocerciasis | 09/26 | 10/26 | | |
| Recruiting | 1/2 | 180 | RoW | Ivermectin Injectable Solution, Montpellier, Injectable Placebo, 0.9% normal saline, Zinc, Placebo empty capsule, Oral Ivermectin | Sohaib Ashraf | Coronavirus Infection, COVID, Sars-CoV2 | 08/21 | 10/21 | | |
NCT05318469: Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 1/2 | 41 | US | Ivermectin, Sklice, Stromectol, Balstilmab | Yuan Yuan, Agenus Inc., Gateway for Cancer Research | Anatomic Stage IV Breast Cancer AJCC V8, Metastatic Triple-Negative Breast Carcinoma | 10/26 | 10/26 | | |
NCT04482686: Trial of Combination Therapy to Treat COVID-19 Infection |
|
|
| Completed | 1 | 31 | US | Ivermectin, Soolantra, Stromectol, Sklice, Doxycycline Hcl, Doxy-100, Monodox, Oracea, Targadox, Acticlate, Morgidox, Avidoxy, Doryx MPC, Mondoxyne NL, Dory, Zinc, Zinc sulphate, Vitamin D3, cholecalciferol-D3, Vitamin C, L-ascorbic acid | ProgenaBiome, Topelia Therapeutics | COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection | 05/22 | 07/22 | | |
| Recruiting | 1 | 30 | RoW | Ivermectin 6 Mg Oral Tablet, Tab. Ivera, Miltefosine Oral Capsule, Cap. Miltefosine | International Centre for Diarrhoeal Disease Research, Bangladesh | Post-kala-azar Dermal Leishmaniasis | 01/24 | 12/24 | | |
NCT04384458: Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis |
|
|
| Recruiting | N/A | 400 | RoW | Hydroxychloroquine, Ivermectin | Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | Coronavirus Infections | 09/20 | 04/21 | | |
| Not yet recruiting | N/A | 218 | Europe | Global management of scabies | Assistance Publique - Hôpitaux de Paris | Scabies | 04/22 | 06/22 | | |
NCT05930002: Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial |
|
|
| Completed | N/A | 120 | RoW | Ivermectin Tablets, Iverzine, Colchicine 0.5 MG, Colchicine, Standared managment | Ain Shams University | COVID-19 | 09/22 | 12/22 | | |
| Completed | N/A | 8767 | RoW | Albendazole 400mg, Zentel, Ivermectin 3 MG, Mectizan, Stromectol | Jennifer Keiser, Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Uganda, Makerere University | Helminthiasis, Intestinal Worms | 07/24 | 10/24 | | |
ACTRN12613000474752: The efficacy of mass drug administration strategies to control scabies in a highly endemic population. |
|
|
| Active, not recruiting | N/A | 2058 | | | Murdoch Childrens Research Institute, Royal Children's Hospital, National Health and Medical Research Council (NHMRC) | Scabies, Skin sores, Other parasitic diseases (strongyloidiasis, ascariasis and trichuriasis), Lymphatic filariasis, Common skin diseases (fungal infections, eczema) | | | | |
| long-acting injectable ivermectin / MedinCell |
| No trials found |
| TAVT-135 / Tavanta Therap |
| No trials found |
